Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Dimple R. Bhatia
Observed names:
Dimple Bhatia,
Dimple R Bhatia
Institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer
Observed institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer,
BioXcel Therapeutics, Inc. (United States),
Vellore Institute of Technology University,
Piramal (India)
show all 6
ORCID:
0000-0001-7916-6991
Observed ORCID:
0000-0001-7916-6991
OpenAlex ID:
A5019345115
DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
2021
·
Allison A Fitzgerald
, Shangzi Wang
, et al.
·
Journal for ImmunoTherapy of Cancer
·
82
PDF
P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models
2007
·
Kalpana S. Joshi
, Maggie J. Rathos
, et al.
·
Molecular Cancer Therapeutics
·
73
Anticancer activity of Ophiobolin A, isolated from the endophytic fungus Bipolaris setariae
2015
·
Dimple R. Bhatia
, Payal Dhar
, et al.
·
Natural Product Research
·
45
A novel mTOR inhibitor is efficacious in a murine model of colitis
2008
·
Mandar R. Bhonde
, Ravindra D. Gupte
, et al.
·
American Journal of Physiology-Gastrointestinal and Liver Physiology
·
37
P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity
2015
·
Archana Jalota-Badhwar
, Dimple R. Bhatia
, et al.
·
Molecular Cancer Therapeutics
·
17
Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway
2008
·
Manoj V. Lohar
, Ramswaroop Mundada
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
16
P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer
2014
·
Venkatasubbaiah A Venkatesha
, Asavari Joshi
, et al.
·
Molecular Cancer
·
11
PDF
Abstract 3054: P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity
2012
·
Kalpana S. Joshi
, Amol Padgaonkar
, et al.
·
Cancer Research
·
8
Synthesis and therapeutic evaluation of pyridyl based novel mTOR inhibitors
2009
·
Vijaykumar Deore
, Nilambari Yewalkar
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
8
Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
2024
·
Rohan Chaubal
, Nilesh Gardi
, et al.
·
Molecular Cancer Research
·
6
PDF
Discovery of P3971 an Orally Efficacious Novel Anticancer Agent Targeting HIF-1α and STAT3 Pathways
2013
·
Pallavi Godse
, Pramod Kumar
, et al.
·
Anti-Cancer Agents in Medicinal Chemistry
·
4
Structure effect of carbon nanovectors in regulation of cellular responses
2013
·
Shashwat S. Banerjee
, Archana Jalota-Badhwar
, et al.
·
Biomaterials Science
·
4
Abstract 3759: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of Rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) as a new therapeutic option for Kras mutated non small cell lung cancer (NSCLC)
2012
·
Veena R. Agarwal
, Asavari Joshi
, et al.
·
Cancer Research
·
3
25 Potential predictive biomarkers for BXCL701 in acute myeloid leukemia (AML)
2022
·
Veena Agarwal
, Shubhendu Trivedi
, et al.
·
Regular and Young Investigator Award Abstracts
·
2
PDF
Dipeptidyl peptidase inhibitor BXCL701 synergizes with immunomodulatory agents in a preclinical model of colorectal cancer (CRC) by altering the function of various components of the immune system.
2019
·
Veena Agarwal
, John MacDougall
, et al.
·
Journal of Clinical Oncology
·
2
Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer
2016
·
Dimple Bhatia
, Padma Thiagarajan
·
Hypoxia
·
2
PDF
Abstract 3742: P7170: A potent and oral phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) inhibitor with anti-tumor and anti-angiogenic activity
2012
·
Veena R. Agarwal
, Asavari Joshi
, et al.
·
Cancer Research
·
2
Abstract 962: The dipeptidyl peptidase inhibitor BXCL701 activates innate immunity followed by adaptive immunity on a molecular and cellular level in a mouse model of pancreatic cancer
2020
·
Veena Agarwal
, John MacDougall
, et al.
·
Cancer Research
·
1
Abstract P3-05-01: Molecular effects of surgical resection on primary breast tumor
2020
·
Sudeep Gupta
, Rohan Chaubal
, et al.
·
Cancer Research
·
1
Abstract LB-077: Dipeptidyl Peptidase Inhibitor BXCL701 synergizes with an OX40-agonist antibody resulting in synergistic anti-tumor response and survival in an animal model of colorectal cancer by bridging the innate and adaptive arms of the immune system
2019
·
Veena R. Agarwal
, John MacDougall
, et al.
·
Cancer Research
·
1
New Emerging Molecules in Cancer Research Which Hold Promise in Current Era
2019
·
Dimple R. Bhatia
, Sushmita Rath
, et al.
·
Springer eBooks
·
1
Abstract 4524: The effect of acute intraoperative hypoxia in breast cancer
2017
·
Dimple R. Bhatia
, Shalaka Joshi
, et al.
·
Cancer Research
·
1
Abstract 4521: P7170, a novel inhibitor of phosphoinositide 3-kinase (PI3K)-mammalian target of rapamycin (mTOR) and activin receptor-like kinase 1 (ALK1) shows anti-tumor activity in triple negative breast cancer
2014
·
Veena R. Agarwal
, Dimple Bhatia
, et al.
·
Cancer Research
·
1
Data from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
2024
·
Rohan Chaubal
, Nilesh Gardi
, et al.
Data from Surgical Tumor Resection Deregulates Hallmarks of Cancer in Resected Tissue and the Surrounding Microenvironment
2024
·
Rohan Chaubal
, Nilesh Gardi
, et al.
Show more works
View as search
Works count:
65
Citation count:
328
H-index:
8
I10-index:
7
Year
Topic
Type
